This week Moderna and Merck announced significant clinical study results that support a strategy of immune priming to expand the effectiveness of immunotherapy checkpoint inhibitors, as is also being developed by Sona with its THT immune modulating therapy, and highlight where THT may offer distinct practical advantages.
The positive Phase 3 results announced by Moderna and Merck provide important external validation for the scientific rationale underlying Sona Nanotech’s Targeted Hyperthermia Therapy (THT). In the INTerpath-001 trial, the addition of Moderna’s individualized neoantigen therapy, intismeran autogene (V940), to Merck’s KEYTRUDA (pembrolizumab) produced statistically significant and clinically meaningful improvements in both recurrence-free survival and distant metastasis-free survival compared with KEYTRUDA alone in patients with resected high-risk melanoma. While detailed Phase 3 results have yet to be presented, the topline outcome provides powerful late-stage evidence supporting a fundamental principle of immuno-oncology: helping the immune system recognize tumor-specific neoantigens can materially improve the effectiveness of checkpoint inhibition. While Sona’s approach achieves this by generating precisely modulated heat within tumors, Moderna’s approach achieves this by sequencing an individual patient’s tumor, identifying relevant mutations and manufacturing a personalized mRNA therapy encoding selected neoantigens to stimulate a tumor-specific immune response.
This development is relevant to Sona particularly because our Targeted Hyperthermia Therapy (THT) aims to achieve a very similar therapeutic objective harnessing a highly conserved natural immune activating phenomenon, fever. Rather than identifying selected important neoantigens from a patient’s tumors to manufacture an individualized vaccine, THT uses Sona’s biocompatible gold nanorods to precisely focus fever-range heat into the core of a tumor. The heat stress focused into the tumor in turn induces immunogenic cancer-cell death, sparing surrounding non-cancerous cells and exposing the patient’s immune system to a multitude of tumor-specific antigens as the immune cells proceed to clean up the dead, antigen-rich tumor cells killed by the heat stress. Sona’s preclinical studies have clearly demonstrated the ability for THT to activate this natural immunological effect in immunologically “cold” tumor models, including microsatellite-stable colorectal cancer, where THT was able to sensitize tumors leading to successful clearance of tumors using standard PD-1 immune checkpoint blockade, like the Keytruda immunotherapy drug used in the Moderna and Merck mRNA study. Sona has also experienced encouraging early human results in a small, safety and feasibility study completed in 2025 treating immunotherapy-refractory advanced melanoma patients. In this 10-patient study, 8 of 10 patients showed a clinical response by day 15, and 6 of the 8 responders had no detectable residual melanoma in representative biopsied tumors. Histological analysis of representative patient tissue also showed immune activation, including natural killer cell infiltration and PD-L1 upregulation, evidence that the immune priming seen preclinically also occurred in human tumors. These results provided the confidence to advance to a larger randomized, controlled study.
From an investor perspective, the Moderna/Merck results provide Phase 3 validation of the broader strategy of immune priming to expand the effectiveness of checkpoint inhibitors shared by Sona. If Sona can demonstrate clinically that THT reliably converts immunologically cold tumors into immune-responsive ones, its value proposition could extend well beyond its direct tumor-killing effect. Our goal is for THT to become an immunotherapy-enabling platform, expanding the population of cancer patients who can benefit from widely used checkpoint inhibitors such as KEYTRUDA. That would create an attractive strategic position for Sona: rather than competing with established immunotherapies, THT could potentially make those therapies effective in cancers and patients where they currently provide limited benefit.
Importantly, THT may ultimately offer practical and economic advantages over individualized cancer vaccines. Moderna’s approach requires tumor sequencing, computational selection of patient-specific neoantigens and manufacture of an individualized mRNA therapy for each patient. THT instead uses the tumor itself as the source of antigens: Sona’s gold nanorods are injected into the tumor and activated with near-infrared light to produce localized therapeutic heat. If successfully validated and commercialized, this approach could potentially be faster, simpler and less expensive to administer, without the individualized manufacturing step required for a personalized vaccine. Moreover, because THT is not dependent upon identifying and manufacturing a predefined set of patient-specific neoantigens, it has the potential to be applicable across a broader range of accessible solid tumors. Sona has already demonstrated preclinical activity across melanoma, colorectal and triple-negative breast cancer models, supporting the potential for a multi-indication platform, although that broader applicability remains to be established clinically.
Taken together, the Moderna/Merck Phase 3 success can be viewed as validation of the destination, rather than of Sona’s particular route to getting there. Moderna and Merck have now demonstrated at Phase 3 that adding a therapy designed to stimulate tumor-specific immune recognition can improve outcomes beyond KEYTRUDA alone. Sona is developing a potentially simpler, non-personalized and broadly applicable means of pursuing that same overarching goal, using targeted hyperthermia to turn the patient’s own tumor into a source of immune stimulation. If the IGNITE-THT study confirms that THT can reproducibly prime cold tumors and restore or enhance responsiveness to checkpoint inhibitors, the combination of clinical efficacy, treatment simplicity, potentially lower cost and applicability across multiple tumor types could represent a compelling differentiation for THT and an important source of value creation for Sona.